Using rTMS to improve motor symptoms in Parkinson's disease
An Open-label Study on the Clinical Efficacy of rTMS Intervention in PD
NA · Anhui Medical University · NCT06542991
This study is testing if a special brain stimulation technique can help improve movement problems in people with Parkinson's disease.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 40 Years and up |
| Sex | All |
| Sponsor | Anhui Medical University (other) |
| Locations | 1 site (Hefei, Anhui) |
| Trial ID | NCT06542991 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of repetitive transcranial magnetic stimulation (rTMS) targeting the supplementary motor area (SMA) in patients with Parkinson's disease. It will involve 20 participants who will be randomly assigned to receive either real or sham stimulation over a period of 7 days. The primary outcome will be measured using the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III scores, assessing changes from baseline to post-treatment and follow-up. Secondary outcomes will include additional clinical symptom scales to further evaluate the intervention's efficacy.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 40 and older with idiopathic Parkinson's disease and specific motor symptom severity.
Not a fit: Patients with secondary parkinsonism syndromes or severe neurological conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly improve motor symptoms in patients with Parkinson's disease.
How similar studies have performed: While rTMS has shown promise in smaller studies, this approach targeting the SMA with neuroimaging guidance is relatively novel and has not been extensively tested in larger clinical trials.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥40 years old 2. Meet Movement Disorder Society standards; 3. Have no history of drug adjustment within 4 weeks before and during treatment; 4. The MDS-UPDRS Ⅲ score ≥8, and the Hoehn-Yahr rating is 1-4 5. MMSE ≥24，able to cooperate with the completion of behavioral tests and transcranial magnetic stimulation therapy. Exclusion Criteria: 1. Head MRI/CT ruled out focal brain injury or severe leukoencephalopathy (Fazekas grade 3); 2. Various secondary parkinsonism syndromes (vascular parkinsonism, Parkinsonism combined with parkinsonism, drug parkinsonism, etc.); 3. Severe craniocerebral trauma, received craniocerebral surgery or deep brain stimulation treatment; 4. There are ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc. 5. The person or first-degree relatives have a history of epilepsy, unexplained loss of consciousness, or are taking anticonvulsant drugs to treat epileptic seizures; 6. Diagnosed with a neuropsychiatric disorder other than PD 7. Have a history of drug abuse or drug use; 8. Participants in any clinical trial within the previous 6 month; 9. Pregnant/lactating women or subjects (including men) who have a birth plan within 6 months; 10. Other conditions deemed unsuitable for inclusion by the investigator.
Where this trial is running
Hefei, Anhui
- Cognitive Neuropsychology Lab Anhui Medical University — Hefei, Anhui, China (RECRUITING)
Study contacts
- Study coordinator: Kai Wang, Ph.D.
- Email: wangkai1964@126.com
- Phone: 055162923704
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Transcranial Magnetic Stimulation, Parkinson Disease, Supplementary Motor Area, Supplementary motor area